Boji Medical Technology Co

Boji Medical Technology Co FCF Yield

The Free Cash Flow Yield of Boji Medical Technology Co (300404.SZ) as of Nov 2, 2026 is 1.73 %. In the previous year, Free Cash Flow Yield was -0.07 % — a change of -2,755.20% (higher).

FCF Yield

1.73 %

YoY

-2,755.20%

Last updated:

Free Cash Flow Yield of Boji Medical Technology Co is 2025 1.73 % . Free Cash Flow Yield of Boji Medical Technology Co was 2024 -0.07 % . It decreases by -2,755.20% higher compared to the previous year.

The Boji Medical Technology Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-0.28 CNY
Jan 1, 2019
-0.73 CNY
Jan 1, 2020
1.67 CNY
Jan 1, 2021
-0.61 CNY
Jan 1, 2022
-2.27 CNY
Jan 1, 2023
-0.67 CNY
Jan 1, 2024
-0.07 CNY
Jan 1, 2025
1.73 CNY
The Boji Medical Technology Co FCF Yield history
YEARFCF YieldYoY
1.73 %-2,755.20%
-0.07 %-90.20%
-0.67 %-70.71%
-2.27 %+275.09%
-0.61 %-136.39%
1.67 %-327.00%
-0.73 %+163.50%
-0.28 %-69.73%
-0.92 %-67.75%
-2.85 %+835.27%
-0.31 %-488.71%
0.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Boji Medical Technology Co Stock analysis

What does Boji Medical Technology Co do? Boji Medical Technology Co., Ltd. generates revenue through comprehensive CRO services for pharmaceutical and medical device development. The company offers preclinical research, clinical trials, data management, biostatistics, and regulatory consulting, primarily serving domestic pharmaceutical companies and research institutions. Their one-stop service model includes drug evaluation, medical device registration, and CDMO services for new drug and device production. The firm's domestic market focus ensures steady demand from local clients seeking regulatory compliance and R&D support. The company's revenue streams are derived from multiple service segments: preclinical studies, clinical research, and technology transfer. These services are tailored to meet the needs of pharmaceutical firms requiring outsourced R&D solutions. CDMO services further enhance their offerings by supporting manufacturing processes alongside development. Domestic clients form the core customer base, leveraging Boji's expertise in navigating China's regulatory landscape for drug and device approvals. Boji Medical Technology's business model centers on providing end-to-end CRO solutions, combining preclinical and clinical research with regulatory support. Their services are designed to accelerate product development cycles for clients, reducing time-to-market for new pharmaceuticals and medical devices. The firm's domestic market strategy aligns with the growing demand for R&D outsourcing within China's healthcare sector. Boji Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Boji Medical Technology Co stock

Free Cash Flow Yield of Boji Medical Technology Co is 1.73 % in 2025.

Free Cash Flow Yield of Boji Medical Technology Co changed from -0.07 % to 1.73 %, representing a -2,755.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Boji Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Boji Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Boji Medical Technology Co

All Key Metrics — Boji Medical Technology Co